Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) — Cash Flow Reinvestment Rate
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Cash Flow Reinvestment Rate of 1.44x as of September 2025, reinvesting CN¥16.64 Million (capex CN¥16.64 Million ) from operating cash flow of CN¥11.57 Million. Check 301211 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Cash Flow Reinvestment Rate (2018–2025)
Historical reinvestment intensity for Hubei Biocause Heilen Pharmaceutical Co. Ltd. across 8 annual periods. Explore 301211 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2018–2025)
Year-by-year capital reinvestment analysis for Hubei Biocause Heilen Pharmaceutical Co. Ltd.. For live market cap and broader valuation context, see 301211 market cap overview.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 8.92x | CN¥67.34 Million | CN¥7.55 Million | CN¥52.33 Million | ▼ -22.8% |
| 2024 | 11.55x | CN¥1.11 Billion | CN¥96.07 Million | CN¥164.43 Million | ▲ +661.3% |
| 2023 | 1.52x | CN¥207.94 Million | CN¥137.06 Million | CN¥186.53 Million | ▲ +48.7% |
| 2022 | 1.02x | CN¥255.82 Million | CN¥250.79 Million | CN¥75.95 Million | ▼ -49.6% |
| 2021 | 2.02x | CN¥250.71 Million | CN¥123.98 Million | CN¥21.07 Million | ▲ +326.1% |
| 2020 | 0.47x | CN¥57.74 Million | CN¥121.67 Million | CN¥13.39 Million | ▼ -38.7% |
| 2019 | 0.77x | CN¥288.37 Million | CN¥372.33 Million | CN¥32.34 Million | ▲ +135.3% |
| 2018 | 0.33x | CN¥25.08 Million | CN¥76.18 Million | CN¥25.08 Million | — |